Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,553 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluids Clear all
Completed Not applicable Interventional Results available

Preemptive Resuscitation for Eradication of Septic Shock

NCT01449721
View directory record Official record
Conditions
Sepsis, Severe Sepsis
Interventions
Intravenous fluid
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 15, 2026, 6:34 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

NCT05013216
View directory record Official record
Conditions
High Risk Cancer, Pancreatic Cancer
Interventions
Cohort A: Patients at high risk of developing pancreatic cancer., Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 6:34 PM EST
Recruiting Not applicable Interventional

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT07541404
View directory record Official record
Conditions
Subdural Hematoma
Interventions
NeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
Device
Lead sponsor
Arsenal Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 15, 2026, 6:34 PM EST
Terminated Phase 4 Interventional Results available

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome

NCT00498485
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Placebo, Sodium Oxybate
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
21 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Nov 15, 2026, 6:34 PM EST
Active, not recruiting Phase 1 Interventional Results available

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

NCT05413304
View directory record Official record
Conditions
Glioma
Interventions
Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra, abemaciclib + temozolomide, Temozolomide, Brain MRI, Brain CT, EKG, Chest X-ray, Biopsy/resection
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 6:34 PM EST
Completed Not applicable Interventional Results available

Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

NCT03846804
View directory record Official record
Conditions
Musculoskeletal Infection, Acute Hematogenous Osteomyelitis, Septic Arthritis, Osteomyelitis, Pyomyositis
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Nov 15, 2026, 6:34 PM EST
Not listed Not applicable Interventional

Performance of the Poseidon System for Fluid Management During Water-aided Colonoscopy

NCT05512026
View directory record Official record
Conditions
Colonic Disease
Interventions
Feasibility Assessment
Device
Lead sponsor
WAE Medical
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Nov 15, 2026, 6:34 PM EST
Completed Phase 1 Interventional

Assessment of Combined Bowel Preparation for Capsule Endoscopy Study

NCT01243736
View directory record Official record
Conditions
Gastrointestinal Hemorrhage
Interventions
Combination Prep
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Nov 15, 2026, 6:34 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 15, 2026, 6:34 PM EST
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Nov 15, 2026, 6:34 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Nov 15, 2026, 6:34 PM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?

NCT06023446
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 15, 2026, 6:34 PM EST
Completed Not applicable Interventional

Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

NCT01058746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
restrictive perioperative fluid management, Liberal perioperative fluid management
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Nov 15, 2026, 6:34 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor

NCT02273115
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Oxytocin, Transcervical Foley catheter
Drug · Device
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 15, 2026, 6:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Ghrelin and Gastric Emptying in Children With Functional Dyspepsia

NCT01591174
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Nov 15, 2026, 6:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Nov 15, 2026, 6:34 PM EST
Completed No phase listed Observational

Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

NCT01799018
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hydrocephalus
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Nov 15, 2026, 6:34 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727
View directory record Official record
Conditions
Glycogen Storage Disease
Interventions
mRNA-3745
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 15, 2026, 6:34 PM EST
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 15, 2026, 6:34 PM EST
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Nov 15, 2026, 6:34 PM EST
Completed Not applicable Interventional

Ultrasound Assessment of Volume in Patients on Continuous Dialysis

NCT03194750
View directory record Official record
Conditions
Volume Overload, Kidney Failure, Respiratory Failure
Interventions
Share ultrasound measurement of IVC collapsibility to Nephrology Attending, Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Nov 15, 2026, 6:34 PM EST
Completed Not applicable Interventional Results available

Negative Pressure Wound Therapy to Reduce Surgical Site Infection

NCT01905397
View directory record Official record
Conditions
Patients Undergoing Hepatopancreatobiliary Surgery
Interventions
Conventional wound therapy, Negative pressure wound therapy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Nov 15, 2026, 6:34 PM EST
Recruiting Phase 2 Interventional

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

NCT06736613
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma of Breast, Diffuse Large B Cell Lymphoma of Testis, HIV-associated Diffuse Large B Cell Lymphoma, Double Expressor DLBCL
Interventions
Cerebral Spinal Fluid ctDNA
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 15, 2026, 6:34 PM EST
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Nov 15, 2026, 6:34 PM EST